ArticleOncogene2020

Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents.

Constantinos G Broustas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.